Chiasma Inc (CHMA) was Downgraded by Barclays to ” Equal Weight” while Lowering the Price Target of the company shares to $ 5.50 from a previous price target of $40 . Earlier the firm had a rating of “Overweight ” on the company shares. Barclays advised their investors in a research report released on Apr 25, 2016.
Chiasma Inc opened for trading at $3.93 and hit $3.93 on the upside on Friday, eventually ending the session at $3.83, with a gain of 0.26% or 0.01 points. The heightened volatility saw the trading volume jump to 5,01,230 shares. Company has a market cap of $93 M.
Chiasma Inc. (Chiasma) is a biopharmaceutical company. The Company is focused on improving the lives of patients suffering from orphan diseases by developing and commercializing oral forms of therapies that are available by injection. Using the Company’s Transient Permeability Enhancer (TPE) technology platform it develops oral therapies associated with existing injectable therapies. It has completed a multinational Phase III clinical trial of its advanced Transient Permeability Enhancer platform-based product candidate oral octreotide for the treatment of acromegaly. The Company through its TPE platform has developed a pipeline of oral product candidates. It offers product oral octreotide for various indications such as Acromegaly-U.S. which has completed Phase III clinical trial; Acromegaly-E.U. which is in Phase III and Neuroendocrine Tumor (NET) and New indication (orphan). The Company’s wholly owned subsidiary is Chiasma (Israel) Ltd.